Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis
Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis
The investigators aim to investigate the safety and efficacy of peripheral blood monocyte for
 the treatment of patients with advanced liver cirrhosis.
G-colony stimulating factor(5ug/kg/day)will be administered twice subcutaneously for 3 days
 to three patients with liver cirrhosis. On the day 4th, plasmapheresis will be done to
 collect peripheral blood mononucleated cells

 . And then we are going to infuse the collected peripheral blood mononucleated cells of their
 own through the portal vein of each patients under ultrasonographic guidance.
Inclusion Criteria:

 1. 20 =< Age < 80

 2. Advanced liver cirrhosis with Child-Pugh score 8 or 9 (including patients who have no
 radiologic evidence of remnant HCC for more than 2 years after treatment)

 Exclusion Criteria:

 1. HBsAg-positive

 2. Active status of hepatocellular carcinoma (HCC) (except patients who have no
 radiologic evidence of remnant HCC for more than 2 years after treatment)

 3. History of hemochromatosis and/or autoimmune hepatitis

 4. Pregnant women or lactating women

 5. Hemoglobin < 8g/dL (male), 7.5g/dL (female) or white blood cell (WBC) <1,500 mm3 or
 Neutrophils <500/mm3 or platelet count <50,000/mm3

 6. Serum creatinine> 1.5 x normal upper limit or creatinine clearance <60 ml/min

 7. Presence of signs of malignant tumors or tumor suspected symptoms, or history of
 malignant tumors with recurrence rate greater than 20% within two years

 8. Gastrointestinal bleeding within the last 3 months or if there is a history of
 spontaneous bacterial peritonitis

 9. Presence of portal vein thrombosis

 10. Presence of acute infections